Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05106530
NCT05106530UnknownNot Applicable

Arrhythmogenic Risk Assessment in Coronary Artery Ectasia Patients

Assiut University1 site in 1 country90 target enrollmentStarted: January 1, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
90
Locations
1
Primary Endpoint
Precence of arrhythmias in 24 hours Holter monitoring
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The investigators thought to explore arrhythmias outcome - hidden arrhythmias, ECG features: Tp-Te interval and Tp-Te/QTc ratio, fQRS among patients with coronary artery ectasia as compared to normal coronary artery patients.

Detailed Description

All patients will be subjected to:

A. Full history taking:

  • Including age, sex, history of DM, HTN, dyslipidemia and Body surface area.

B. Holter monitoring for 24 hours:

  • Heart rate variability
  • Hidden arrhythmias
  • Hidden ischemia by monitoring ST segment changes

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects with suspected CAD who are referred for elective coronary angiography and/or interventions

Exclusion Criteria

  • •Patients with a history of cardiomyopathy and myocardial infarction (MI), left ventricular hypertrophy (LVH), pathological Q wave on ECG, typical left bundle block or right bundle block, incomplete right bundle block, or paced rhythm on ECG.
  • •Patients with severe renal impairment
  • •Post CABG patients
  • •Patients of acute coronary syndrome

Outcomes

Primary Outcomes

Precence of arrhythmias in 24 hours Holter monitoring

Time Frame: 1 year

Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.

Secondary Outcomes

  • • Heart rate variability in Holter monitoring(1 year)
  • • Silent ischemia as detected by Holter(1 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mark Mohsen Nady Kamel

Resident at Cardiology Department

Assiut University

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Cardiomyopathy Arrhythmia Risk EvaluationCardiomyopathy
NCT02560844University Health Network, Toronto164
Completed
Not Applicable
Changes in Heart Rhythms Associated With Antipsychotic Drug TreatmentSchizophreniaBipolar DisorderSchizoaffective Disorder
NCT00538122Vanderbilt University12
Completed
Not Applicable
Innovative Stratification of Arrhythmic Risk (ISAR-Trial): ElderyMyocardial Infarction
NCT00196300Deutsches Herzzentrum Muenchen500
Unknown
Not Applicable
ARrhythmias in MYocarditisEndomyocardial BiopsyArrythmiaBiomarkerHeart FailureMyocarditisCardiomyopathySudden Cardiac Death
NCT03801681Medical University of Warsaw100
Completed
Not Applicable
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 AgonistsPulmonary Disease, Chronic Obstructive
NCT03405363Boehringer Ingelheim65,406